Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

Stefan Kostense; Wouter Koudstaal; Mieke Sprangers; Gerrit Jan Weverling; Germaine Penders; Niels Helmus; Ronald Vogels; Margreet Bakker; Ben Berkhout; Menzo Havenga; Jaap Goudsmit

doi:10.1097/00002030-200405210-00019

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

AIDS. 2004 May 21;18(8):1213-6. doi: 10.1097/00002030-200405210-00019.

Authors

Stefan Kostense¹, Wouter Koudstaal, Mieke Sprangers, Gerrit Jan Weverling, Germaine Penders, Niels Helmus, Ronald Vogels, Margreet Bakker, Ben Berkhout, Menzo Havenga, Jaap Goudsmit

Affiliation

¹ Crucell Holland BV, Leiden, The Netherlands.

PMID: 15166541
DOI: 10.1097/00002030-200405210-00019

Abstract

The seroprevalence of adenovirus types 5 (Ad5) and 35 (Ad35) was investigated in patients at risk of AIDS. The seroprevalence of Ad5 was higher than Ad35 in HIV-infected patients from The Netherlands (60% versus 7%) and sub-Saharan Africa (90% versus 20%). The seroprevalence was similar among HIV-infected and uninfected individuals, and remained constant during progression to AIDS. Ad35 is less prone to neutralization than Ad5, encouraging the further development of Ad35 for vaccination against HIV.

MeSH terms

Acquired Immunodeficiency Syndrome / blood
Acquired Immunodeficiency Syndrome / immunology
Acquired Immunodeficiency Syndrome / virology*
Adenoviruses, Human / immunology
Adenoviruses, Human / isolation & purification*
Africa South of the Sahara / epidemiology
Antibodies, Viral / blood*
Genetic Vectors
Humans
Netherlands / epidemiology
Risk Factors
Seroepidemiologic Studies

Substances

Antibodies, Viral